238 related articles for article (PubMed ID: 9544745)
1. Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia. The Familial Hypercholesterolaemia Regression Study Group.
Sun XM; Patel DD; Knight BL; Soutar AK
Atherosclerosis; 1998 Jan; 136(1):175-85. PubMed ID: 9544745
[TBL] [Abstract][Full Text] [Related]
2. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia.
Heath KE; Gudnason V; Humphries SE; Seed M
Atherosclerosis; 1999 Mar; 143(1):41-54. PubMed ID: 10208479
[TBL] [Abstract][Full Text] [Related]
3. Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia.
Jeenah M; September W; Graadt van Roggen F; de Villiers W; Seftel H; Marais D
Atherosclerosis; 1993 Jan; 98(1):51-8. PubMed ID: 8457250
[TBL] [Abstract][Full Text] [Related]
4. Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects.
Raal FJ; Pilcher G; Rubinsztein DC; Lingenhel A; Utermann G
Atherosclerosis; 1997 Feb; 129(1):97-102. PubMed ID: 9069523
[TBL] [Abstract][Full Text] [Related]
5. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis.
Thompson GR; Maher VM; Matthews S; Kitano Y; Neuwirth C; Shortt MB; Davies G; Rees A; Mir A; Prescott RJ
Lancet; 1995 Apr; 345(8953):811-6. PubMed ID: 7898227
[TBL] [Abstract][Full Text] [Related]
6. High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia.
Wierzbicki AS; Lumb PJ; Semra YK; Crook MA
QJM; 1998 Apr; 91(4):291-4. PubMed ID: 9666952
[TBL] [Abstract][Full Text] [Related]
7. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia.
Miltiadous G; Xenophontos S; Bairaktari E; Ganotakis M; Cariolou M; Elisaf M
Pharmacogenet Genomics; 2005 Apr; 15(4):219-25. PubMed ID: 15864114
[TBL] [Abstract][Full Text] [Related]
8. Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia.
Wierzbicki AS; Lumb PJ; Cheung J; Crook MA
QJM; 1997 Oct; 90(10):631-4. PubMed ID: 9415344
[TBL] [Abstract][Full Text] [Related]
9. Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia.
Kajinami K; Yagi K; Higashikata T; Inazu A; Koizumi J; Mabuchi H
Am J Cardiol; 1998 Jul; 82(1):113-7. PubMed ID: 9671018
[TBL] [Abstract][Full Text] [Related]
10. Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations.
Sijbrands EJ; Lombardi MP; Westendorp RG; Leuven JA; Meinders AE; Van der Laarse A; Frants RR; Havekes LM; Smelt AH
Atherosclerosis; 1998 Feb; 136(2):247-54. PubMed ID: 9543095
[TBL] [Abstract][Full Text] [Related]
11. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.
Rubba P; Gentile M; Marotta G; Iannuzzi A; Sodano M; De Simone B; Jossa F; Iannuzzo G; Giacobbe C; Di Taranto MD; Fortunato G
Eur J Prev Cardiol; 2017 Jul; 24(10):1051-1059. PubMed ID: 28353356
[TBL] [Abstract][Full Text] [Related]
12. Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low-density-lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment.
Vuorio AF; Ojala JP; Sarna S; Turtola H; Tikkanen MJ; Kontula K
J Intern Med; 1995 Jan; 237(1):43-8. PubMed ID: 7830029
[TBL] [Abstract][Full Text] [Related]
13. Atherosclerosis in cholesterol-fed rabbits and in homozygous and heterozygous LDL receptor-deficient humans.
Thompson GR
Atherosclerosis; 2018 Sep; 276():148-154. PubMed ID: 30064057
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia.
Feher MD; Webb JC; Patel DD; Lant AF; Mayne PD; Knight BL; Soutar AK
Atherosclerosis; 1993 Nov; 103(2):171-80. PubMed ID: 8292093
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FHMarburg (FH p.W556R).
Schaefer JR; Kurt B; Sattler A; Klaus G; Soufi M
Clin Res Cardiol Suppl; 2012 Jun; 7(Suppl 1):2-6. PubMed ID: 22528129
[TBL] [Abstract][Full Text] [Related]
16. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia.
Couture P; Brun LD; Szots F; Lelièvre M; Gaudet D; Després JP; Simard J; Lupien PJ; Gagné C
Arterioscler Thromb Vasc Biol; 1998 Jun; 18(6):1007-12. PubMed ID: 9633944
[TBL] [Abstract][Full Text] [Related]
17. Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia.
O'Neill FH; Patel DD; Knight BL; Neuwirth CK; Bourbon M; Soutar AK; Taylor GW; Thompson GR; Naoumova RP
Arterioscler Thromb Vasc Biol; 2001 May; 21(5):832-7. PubMed ID: 11348882
[TBL] [Abstract][Full Text] [Related]
18. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
Jensen HK
Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
[TBL] [Abstract][Full Text] [Related]
19. Response to drugs and diet in a compound heterozygote for familial hypercholesterolaemia.
Gudnason V; Muller DP; Lloyd JK; Humphries SE
Arch Dis Child; 1995 Dec; 73(6):538-40. PubMed ID: 8546515
[TBL] [Abstract][Full Text] [Related]
20. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.
Kastelein JJ; Besseling J; Shah S; Bergeron J; Langslet G; Hovingh GK; Al-Saady N; Koeijvoets M; Hunter J; Johnson-Levonas AO; Fable J; Sapre A; Mitchel Y
Lancet; 2015 May; 385(9983):2153-61. PubMed ID: 25743173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
